Daily intelligence on the peptide research industry.

Research Pipeline

MOTS-c: The Mitochondria-Encoded Peptide With a Decade of Preclinical Evidence and a Critical FDA Compounding Vote Eleven Days Away

MOTS-c, a 16-amino acid peptide encoded within mitochondrial DNA, is set for formal FDA advisory review on 23 July 2026 as part of the PCAC's evaluation of seven peptides for the 503A Bulk Drug Substances List. FDA briefing documents propose that it should not be listed, citing insufficient human data and characterisation gaps — yet a Phase 2a trial in prediabetes is now registered, adding new urgency to procurement decisions for UK research labs.

25 Jul 2026

Research Pipeline

KPV: The Alpha-MSH Tripeptide With Two Decades of Preclinical Evidence and an FDA Compounding Vote Nine Days Away

KPV (Lys-Pro-Val) is a three-amino-acid fragment of alpha-melanocyte-stimulating hormone with a substantive body of preclinical evidence in inflammatory bowel disease, wound healing, and dermatology. On 23 July 2026, it faces its first formal FDA scientific review at the Pharmacy Compounding Advisory Committee — and the agency's own briefing documents lean against listing it on the 503A Bulk Drug Substances List.

25 Jul 2026

Research Pipeline

Thymosin Alpha-1: The Thymic Peptide With Four Decades of Clinical Evidence and a Divided Global Regulatory Map

Thymosin alpha-1 (Tα1) occupies a singular position in the peptide landscape: it is approved as a prescription medicine in more than 35 countries under the brand name Zadaxin, yet it holds no FDA approval in the United States and no MHRA marketing authorisation in the UK. This briefing reviews the compound's mechanism, the depth of its clinical evidence base, its evolving US compounding status, and what the regulatory asymmetry means for UK research-procurement professionals.

25 Jul 2026

Research Pipeline

Emideltide (DSIP): The Nine-Amino-Acid Sleep Peptide With Five Decades of Mixed Evidence Now Facing Its First FDA Compounding Review

Delta sleep-inducing peptide — designated Emideltide in US regulatory materials — is the least-discussed substance on the FDA Pharmacy Compounding Advisory Committee's July 24 agenda. Its clinical evidence base is older and narrower than many peptides in the grey market, yet it covers two areas of genuine unmet need: treatment-resistant insomnia and opioid withdrawal. FDA staff scientists have already recommended against listing it, setting up a pointed test of how the reconstituted advisory…

25 Jul 2026

Research Pipeline

TB-500: The Thymosin Beta-4 Fragment Facing a Hostile FDA Briefing Document Four Days Before Its First Compounding Vote

TB-500, a synthetic seven-amino-acid fragment of thymosin beta-4, is scheduled for review by the FDA's Pharmacy Compounding Advisory Committee on 23 July 2026. The agency's pre-published briefing document proposes that neither the free base nor the acetate form be added to the 503A Bulk Drug Substances List, citing failures of chemical characterisation and an absence of adequate human clinical evidence for wound healing.

25 Jul 2026

Research Pipeline

Epitalon: The Telomere Tetrapeptide Heading Into Its First FDA Compounding Vote Tomorrow

Epitalon — a synthetic four-amino-acid peptide derived from pineal gland extract — faces its first formal FDA compounding review on 24 July 2026, the second day of the PCAC meeting at White Oak. With fresh independent evidence from a 2025 Biogerontology study, a negative FDA staff recommendation, and reported conflicts of interest on the panel itself, the regulatory moment is more contested than the peptide's three decades of largely preclinical research would suggest.

25 Jul 2026

Research Pipeline

Tesamorelin: The Only FDA-Approved GHRH Peptide — and What Its Regulatory Journey Tells the Research Community

Tesamorelin (Egrifta) stands apart from the peptides currently before the FDA's Pharmacy Compounding Advisory Committee: it already holds three successive FDA approvals, backed by Phase III randomised controlled trials. Understanding how it got there — and what that means for compounding access, off-label research, and the GHRH class more broadly — is increasingly relevant for procurement professionals as the July 2026 PCAC meeting unfolds.

25 Jul 2026

Research Pipeline

MOTS-c: The Mitochondrial Peptide at the Centre of the July 2026 PCAC Review

MOTS-c, a 16-amino-acid peptide encoded by mitochondrial DNA, is one of four compounds scheduled for discussion on Day 1 of the FDA's Pharmacy Compounding Advisory Committee meeting on 23 July 2026. With the deadline for oral testimony registration falling on 30 June, UK research-procurement professionals have a narrow window to understand what the evidence base actually shows — and what a favourable committee recommendation would and would not mean.

04 Jul 2026

Research Pipeline

Retatrutide: What the TRIUMPH-1 Phase 3 Data and NDA Timeline Mean for Peptide Research Procurement

Eli Lilly's triple-agonist retatrutide posted a 28.3% average weight loss at 80 weeks in the Phase 3 TRIUMPH-1 trial — the largest efficacy signal ever recorded in a randomised obesity study. With an NDA submission targeted for Q4 2026 and a grey market already active, procurement teams need to understand what the compound is, where it stands legally, and how to source it responsibly for legitimate research.

25 Jun 2026

Research Pipeline

Semax: The Russian-Approved Neuropeptide Now at the Centre of the FDA's July 2026 Compounding Review

Semax, a synthetic ACTH-derived heptapeptide approved in Russia for stroke recovery and cognitive impairment, was removed from the FDA's Category 2 restricted compounding list in April 2026 and is now scheduled for formal PCAC review on 24 July 2026. For UK research-procurement teams, its regulatory trajectory — and the evidentiary questions the advisory panel must resolve — make it one of the more consequential peptides to monitor this summer.

01 Jun 2026

Research Pipeline

Oral Peptide Therapeutics Reach an Inflection Point: ICOTYDE's Approval, Pinnacle's $89M Raise, and What the Delivery Revolution Means for Research Labs

The FDA approval of icotrokinra (ICOTYDE) as the first targeted oral peptide to block the IL-23 receptor marks a structural shift in peptide drug delivery. Combined with a wave of investment in oral-peptide platforms and an upcoming PCAC advisory meeting, the field is entering a period of rapid technical and regulatory change that procurement teams need to understand.

29 May 2026

Research Pipeline

What the 2026 Orthopaedic Literature Says About Research Peptides — and Why It Matters for Procurement

A peer-reviewed review in JAAOS: Global Research & Reviews has systematically mapped the mechanism and evidence base for BPC-157, TB-500, GHK-Cu, Ipamorelin, CJC-1295 and related compounds in musculoskeletal medicine. The findings underscore a persistent gap between preclinical promise and human trial data — a distinction that carries direct implications for research-procurement professionals sourcing these compounds and for how suppliers should frame their documentation.

28 May 2026